Literature DB >> 16099713

A proposal of the diagnostic scale of drug-induced liver injury.

Hajime Takikawa1, Morikazu Onji.   

Abstract

Entities:  

Year:  2005        PMID： 16099713     DOI： 10.1016/j.hepres.2005.05.007

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  11 in total

1.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

2.  Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.

Authors:  Kazuto Tajiri; Kengo Kawai; Toshiro Sugiyama
Journal:  J Gastroenterol       Date:  2016-10-27       Impact factor: 7.527

3.  An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis.

Authors:  Akiko Hisamochi; Masayoshi Kage; Tatsuya Ide; Teruko Arinaga-Hino; Keisuke Amano; Reiichiro Kuwahara; Kei Ogata; Ichiro Miyajima; Ryukichi Kumashiro; Michio Sata; Takuji Torimura
Journal:  J Gastroenterol       Date:  2015-10-30       Impact factor: 7.527

4.  NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Authors:  M Richardson; J Kirkham; K Dwan; D J Sloan; G Davies; A L Jorgensen
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

5.  Drug-induced hypersensitivity syndrome associated with reactivation of human herpesvirus 6 presenting with severe hepatic injury.

Authors:  Hideaki Miura; Masayuki Nakano; Naoki Yoshimura; Shigehiro Kitamura; Haruki Yamada; Masakazu Takazoe
Journal:  Clin J Gastroenterol       Date:  2008-09-03

6.  Outcome evaluation of an intervention to improve the effective and safe use of meropenem.

Authors:  Yusuke Yagi; Masafumi Okazaki; Hiromi Higaki; Megumi Nakai; Ayumu Hirata; Mitsuhiko Miyamura
Journal:  Int J Clin Pharm       Date:  2014-04-20

7.  Acute infection by hepatitis E virus with a slight immunoglobulin M antibody response.

Authors:  Yuki Inagaki; Yukio Oshiro; Mamiko Imanishi; Kazunori Ishige; Masaharu Takahashi; Hiroaki Okamoto; Nobuhiro Ohkohchi
Journal:  Clin J Gastroenterol       Date:  2015-07-28

8.  Histological Changes in Autoimmune Hepatitis with Graves' Disease: A Child Case Report.

Authors:  Mamiko Yamada; Hironori Shibata; Yohei Masugi; Tomohiro Ishi; Kaori Kameyama; Hirotoshi Ebinuma; Tomonobu Hasegawa
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

9.  Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin.

Authors:  Noriyuki Kuniyoshi; Hiroshi Miyakawa; Kotaro Matsumoto; Hiromichi Tsunashima; Katsunori Sekine; Takayuki Tsujikawa; Masatoshi Mabuchi; Shinpei Doi; Kentaro Kikuchi
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

10.  NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Authors:  Junichi Azuma; Masako Ohno; Ryuji Kubota; Soichiro Yokota; Takayuki Nagai; Kazunari Tsuyuguchi; Yasuhisa Okuda; Tetsuya Takashima; Sayaka Kamimura; Yasushi Fujio; Ichiro Kawase
Journal:  Eur J Clin Pharmacol       Date:  2012-11-14       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.